Redeye comments on the Q2 report and shortly discusses the two major events during and after the quarter, setting a new direction for AroCell. It has been a turbulent couple of months for the company and the stock, and we await a communicated new strategy with the IDL Biotech merger before we present a more detailed review of the case.